Allarity Therapeutics, Inc. has reached a settlement agreement with Novartis Pharma AG regarding a significant financial liability. On October 28, 2026, the company entered into a Settlement and Release Agreement to resolve an aggregate current liability of $4.9 million, which arose from a previous license agreement with Novartis. The settlement is particularly important for Allarity as it aims to strengthen its financial position amidst ongoing challenges in the pharmaceutical industry.

As part of the agreement, Novartis has agreed to accept a payment of $1 million from Allarity as full settlement of the liability. Upon receipt of this payment, both parties will release each other from any claims related to the liability, with exceptions only for claims arising from the enforcement of the Settlement Agreement.

Background

Allarity Therapeutics, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates as an emerging growth company listed on the Nasdaq under the ticker symbol ALLR. The company focuses on developing innovative therapeutic solutions, and its recent filings indicate a strategic shift towards enhancing its laboratory services. The latest filing, dated November 2, 2026, outlines the settlement agreement and its implications for the company's future.

What the Filing Says

The filing states, "On October 28, 2026, Allarity Therapeutics, Inc. entered into a Settlement and Release Agreement with Novartis Pharma AG relating to an aggregate current liability of $4,900,000, plus interest, due to Novartis." It further details that the liability arose under a license agreement previously terminated in January 2024.

Impact

This settlement may have significant implications for Allarity Therapeutics, particularly in terms of financial stability and future business operations. By resolving this liability, the company can focus on its core activities and strategic initiatives without the burden of outstanding financial obligations. The resolution may also enhance Allarity's credibility with potential partners and investors in the competitive pharmaceutical landscape.

What's Next

The filing does not specify what happens next following the settlement. However, the company has already indicated a shift towards revenue-generating contracts through its newly established CLIA-certified laboratory services strategy, as announced in a press release on October 30, 2026.